focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I will take that one on board HbD.
If it is not MEI then l do not have an idea who the on licensee is. It may well be that they have indicated they can raise sufficient funds to continue development.
As to why the company is not named, to that l am still at a loss.
Regards
Afternoon SOG - I think you're incorrect to suggest, "Licence not yet agreed as l would deem raising of finances a prior requisite" as that would seem to go against SAR's own website which notes, "...is now licensed to a private US-based bioharma company" and also the business weekly article that states, "...has signed a licence agreement for SRA737" so it would appear to be a done deal rather than still hanging in the balance.
https://sareum.com/research-development/#our-overview
https://www.businessweekly.co.uk/posts/sareum-shares-soar-as-it-starts-to-cash-in-on-cancer-programme
SRA737 reminder: https://s28.q4cdn.com/726829854/files/doc_downloads/events/ASCO-SRA737-Analyst-Call-Presentation_final.pdf
Proof-of-concept activity in multiple indications
Anti-cancer activity correlated with genetics
Very promising anogenital cancer signal
Anogenital cancer: tractable opportunity to potentially pursue registration-intent studies
- unmet medical need; low historical ORR/PFS in 2L
- substantial potential market opportunity
- anogenital P2 cost estimated at $10M
PARPi & IO combinations provide compelling additional opportunities
Any companies that have an interest in 737 would also be aware of resistance development via the cancer using an alternative pathway at the P53 checkpoint.
The only real expert in this field is Michelle Garrett continuing research up until 2021 seeking suitable in combination compounds.
There are a few others that have researched but am not aware of any innovative breakthroughs.
Regards
The CPF granted Sierra Oncology a reduction in milestone payment after no development for 12xmonths, 12 months later SO we're claiming final trial design and 12 months after that Sierra Oncology announced they would be hading it back to the CPF.
From what info we have been given the terms of the licence are nigh identical to original agreement.
Sorry, Potnak, more detail here https://www.cambridgenetwork.co.uk/news/link-china-pharma-solutions-brokers-sareum-co-development-agreement-china-auroraflt3
I don’t think for a minute the CPF would re license SRA737 without the licensee providing a full rationale of moving it forward at pace especially after the delays it suffered under Sierra. Any interested parties have had access to SRA737 to run any pre clinical combinations prior to licensing. It’s P3 ready and looks extremely promising in many combination trials. IMO we will hear something as soon as funding is in place and they have had it coming up 2 months now….
Hi Potnak - it was Hebei Medical University Biomedical Engineering Center - http://www.chinabiotoday.com/articles/20131203_1
"I am still under the firm belief that our CcT245737 would have and now more likely to knock the spots off the GSK obtained Tesaro pipeline that GSK bought for 5.1 billion dollars."
Just like some people were in the firm belief that if they flapped their arms fast enough they could fly
I don't think we ever found out who the specialty Chinese pharma was took Aurora was either. They will sing from the rooftops once they know they have something. Or we'll get a Friday afternoon RNS saying it will be handed back. Im not even sure they will run trials, they might just pull a data package together to get funding first. I feel like 737 could be something but it's further away than 1801 1b IMO.
No idea as such.
Licence not yet agreed as l would deem raising of finances a prior requisite.
If it were announced there is nothing to stop a company coming in with a higher offer and shelve 737 again.
737 has vast potential especially in ano genital. Gains to be had also in BRCA1 and may be BRCA2.
In addition difficult to treat cancers such as pancreatic and HGSOC.
I am still under the firm belief that our CcT245737 would have and now more likely to knock the spots off the GSK obtained Tesaro pipeline that GSK bought for 5.1 billion dollars.
A lot of money to lose out to a competitor!
Regards
Hi SOG - the question is, if 737 is now with MEI, why the radio silence on it? What do they stand to gain in keeping it under wraps?
There were HNWI investing at 8p+ , £4+ in today’s money. So I can’t see an offer in the region of £3 being acceptable.
There is no shortage of interest with CHK1 inhibitors
https://www.nature.com/articles/s12276-022-00863-4
GlenFidrich.
My thinking is along the lines of people involved historically.
The involvement of Nick Glover who was CEO of Sierra Onology when 737 licenced to them
Plenty of good work carried out.
Michelle Garrett was an advisor to Sierra Oncology.
Sierra ceased development of 737 to concentrate on Momoletonib, even to the point of robbing funds that had been allocated to 737.
Nick Glover resigns.
Sierra Oncology played the game of drawing out progress to nigh 3 years. Reduced milestone payment had been agreed after a year of no development and in effect no further progress made with except 'final design stage'
Michelle Garrett had been working on developing in combo therapies with CHK1 inhibitors beyond discontinuation by Sierra Oncology.
GSK buy SO for 1.9 billion meeting their main objective for Momoletonib commercialisation.
If this as they stated was the main purpose then what may we ask were the other objectives?
At time of sale there was an uproar and nigh revolt by shareholders believing that SO had been way undervalued with consequent sake. Soon after thus Steve Dilley the CEO of SO resigned with plenty of perks ie around 1.5 million dollars.
Why did he resign?
You also have work carried out my Michelle Garrett in some form or another involving Nick Glover and 737 ( alternative resistance pathways from memory)
We,also have the 500,000 shares. At present MEI around 4 dollars a share. Market Cap of around 30 million dollars.
On addition the info given regards milestone payments is nigh an identical continuation of the licence agreement made between the CPF and Pronai Therapeutics.
There are too many coincidences here.
Regards
'Private' could mean a company created as a vehicle to develop 737 - separate to the actual company(s) involved.
SOG, the wording of the recent RNS ("the CRT Pioneer Fund has entered into a development and commercialization license agreement for SRA737 with a PRIVATE biopharma company based in the United States") would seem to rule out MEI Pharma surely? But what about Allorion Therapeutics? It fits the profile...
https://alloriontx.com
https://www.prnewswire.com/news-releases/allorion-therapeutics-a-next-generation-precision-medicine-company-focusing-on-oncology-and-autoimmune-diseases-raises-50-million-series-b-financing-301767570.html
Good to see a tick up in IR/marketing. It's been on LinkedIn as well.
Speaking of tick up, the SP is looking perky (again).
Https://x.com/sareumplc/status/1760242418492846435?s=46&t=-wmIODjcUbTMyoVNmalovA
The tie to to MEI ìs NICK GLOVER. I have posted recently on this which gives far more incite of Sierra Oncology, Nick Glover 737, resignation of Nick Glover, Michelle Garrett involvement and of ourselves the whole debacle of SO withdrawing 737 from the shop window around a month before Nick Glovers resignation.
Regards
Agreed luton. £3 now would be the equivalent of 6p in old money, which is where I was selling in 2021. So not sure it's the end game that many LTH's had in mind, or they'd have sold already.
To save everyone googling away the minutes in their day a brief history of Mei Pharma which all sounds encouraging
MEI Pharma: A Summary History
Founding and Early Years (2010-2014):
Formed in 2010 by Daniel Gold, Ph.D., with a focus on developing novel therapies for cancer.
Initially focused on acquiring and developing CDK inhibitors, a class of drugs targeting cell cycle regulation.
Secured funding through several venture capital rounds and grants.
Shifting Focus and Growth (2014-2023):
Expanded pipeline in 2014 with the acquisition of MEI Pharma (originally known as Mirabilis Pharmaceuticals).
Gained access to ME-344, a potential treatment for solid tumors, and Voruciclib, a CDK9 inhibitor.
Advanced both drugs through clinical trials, with Voruciclib reaching Phase 3 for acute myeloid leukemia (AML).
Focused on partnerships and collaborations with other pharmaceutical companies.
Recent Developments (2023-Present):
Presented positive clinical data on Voruciclib at the American Society of Hematology (ASH) annual meeting in December 2023.
Announced design of ongoing Phase 2 clinical study for ME-344 at the ASCO Gastrointestinal Cancers Symposium in January 2024.
Released 2023 annual report highlighting financial performance and operational progress.
Continued focus on developing best-in-class cancer therapies and improving patient outcomes.
Key Points:
Founded in 2010, MEI Pharma has grown from a small, research-focused company to a clinical-stage pharmaceutical entity.
The company primarily focuses on developing novel cancer therapies, particularly CDK inhibitors.
Its lead drugs, Voruciclib and ME-344, are currently in clinical trials for various cancer indications.
MEI Pharma is committed to partnerships, collaborations, and continuous development to bring innovative treatments to patients.
If Mei had licensed 737 they'd have had to announce it here within a day of signing the agreement - https://www.sec.gov/edgar/search/#/dateRange=1y&ciks=0001262104&entityName=MEI%2520Pharma%252C%2520Inc.%2520(MEIP)%2520(CIK%25200001262104)
Only worry if an offer was made at the moment. A very low ball offer wouldn't break much ice.
But the reality of something like 10 x current SP such as about £3 per share probably would. It would suit me but not a lot of other long term holders.
Some good news required to propel the share price towards à more realistic level and then any offer for a buyout would be much better appreciated.
With a market cap of just £29million and a world class product /s it will only be a matter of time before Sareum will be taken over.
I would imagine several companies are running the ruler over them right now.
I would if I were in this area.